← All trials
NCT06644573
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2024
- Primary completion
- May 1, 2025
- Completion date
- May 1, 2025
- First posted
- Oct 16, 2024
- Last posted
- Nov 1, 2024
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PROSOMNIA Sleep Health & WellnessLead sponsor
- Mayo ClinicCollaborator
- PROSOMNIA Sleep Health & WellnessCollaborator
- PROSOMNIA Sleep Health & WellnessSponsor investigator
- Memorial Healthcare SystemOfficial
Drugs studied
Indications studied
- Cancer Pain
- Occupational Stress
- Military Health
- Sleep Quality
- Alzheimer Disease
- Anesthesia
- Anxiety
- Anxiety Disorders
- Mental Disorders
- Circadian Rhythm
- Depression
- Dreams
- Sleep Initiation and Maintenance Disorders
- Menopause
- Mental Health
- Pain
- Parkinson Disease
- Sleep
- Sleep Deprivation
- Sleep, REM
- Stress Disorders, Post-Traumatic
- Traumatology
- Veterans
- Idiopathic Hypersomnia
- Sleep Disorders, Circadian Rhythm
- REM Sleep Behavior Disorder
- Sleep Disorders, Intrinsic
- Chronobiology Disorders
- Athletes
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.